Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Department of Pediatrics, Section of Hematology/Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States of America; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States of America.
Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Department of Pediatrics, Section of Hematology/Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States of America; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States of America.
Gynecol Oncol. 2020 Aug;158(2):467-475. doi: 10.1016/j.ygyno.2020.05.007. Epub 2020 Jun 5.
Ovarian germ cell tumors (GCTs) are rare in adults, but are more common in adolescents and young adults. Contemporary management of ovarian GCTs is evolving as collaboration among pediatric, medical, and gynecologic oncologists increases, and studies increasingly incorporate female adult patients. Despite an improved understanding of ovarian GCT, many questions remain. Areas of continued controversy include which stage I ovarian GCTs and immature teratomas can be observed without adjuvant therapy, appropriate risk classification for ovarian GCT, surveillance strategies, and optimal therapy for recurrence. These topics as well as active areas of clinical investigation are discussed.
卵巢生殖细胞肿瘤(GCT)在成年人中较为罕见,但在青少年和年轻女性中更为常见。随着儿科、内科和妇科肿瘤学家之间的合作不断增加,以及越来越多的成年女性患者纳入研究,卵巢 GCT 的治疗方法也在不断发展。尽管对卵巢 GCT 的认识有所提高,但仍有许多问题尚未解决。目前仍存在争议的领域包括:哪些 I 期卵巢 GCT 和未成熟畸胎瘤可以不进行辅助治疗而进行观察;卵巢 GCT 的适当风险分类;监测策略;以及复发性疾病的最佳治疗方法。本文将对这些主题和当前临床研究的热点领域进行讨论。